168 related articles for article (PubMed ID: 32095563)
1. Treatment of symptomatic splenomegaly with low doses of radiotherapy: Retrospective analysis and review of the literature.
de la Pinta C; Fernández Lizarbe E; Montero Luis Á; Domínguez Rullán JA; Sancho García S
Tech Innov Patient Support Radiat Oncol; 2017; 3-4():23-29. PubMed ID: 32095563
[TBL] [Abstract][Full Text] [Related]
2. Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma.
Ishibashi N; Maebayashi T; Aizawa T; Sakaguchi M; Abe O; Saito T; Tanaka Y
Hematology; 2015 May; 20(4):203-7. PubMed ID: 25131182
[TBL] [Abstract][Full Text] [Related]
3. Palliative splenic irradiation for symptomatic splenomegaly in non-Hodgkin lymphoma.
Oliveira LC; Fardilha C; Louro M; Pinheiro C; Sousa A; Marques H; Costa P
Ecancermedicalscience; 2018; 12():887. PubMed ID: 30792804
[TBL] [Abstract][Full Text] [Related]
4. Low dose palliative radiotherapy for splenomegaly in hematologic disorders.
Lavrenkov K; Krepel-Volsky S; Levi I; Ariad S
Leuk Lymphoma; 2012 Mar; 53(3):430-4. PubMed ID: 21848363
[TBL] [Abstract][Full Text] [Related]
5. Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.
Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):17-22. PubMed ID: 11163493
[TBL] [Abstract][Full Text] [Related]
6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
7. Low-dose splenic irradiation in symptomatic congestive splenomegaly: report of five cases with literature data.
Bruns F; Bremer M; Dettmer A; Janssen S
Radiat Oncol; 2014 Mar; 9():86. PubMed ID: 24673965
[TBL] [Abstract][Full Text] [Related]
8. Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
Shen S; DeNardo GL; Yuan A; Hartmann-Siantar C; O'Donnell RT; DeNardo SJ
Cancer Biother Radiopharm; 2005 Dec; 20(6):662-70. PubMed ID: 16398618
[TBL] [Abstract][Full Text] [Related]
9. Short-time splenic irradiation for splenomegaly.
Schratter-Sehn AU; Cerveny M; Simmel H; Schlögl E; Schratter A
Onkologie; 2003 Feb; 26(1):21-4. PubMed ID: 12624513
[TBL] [Abstract][Full Text] [Related]
10. Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients.
Kitanaka A; Takenaka K; Shide K; Miyamoto T; Kondo T; Ozawa K; Kurokawa M; Akashi K; Shimoda K
Int J Hematol; 2016 Apr; 103(4):423-8. PubMed ID: 26791378
[TBL] [Abstract][Full Text] [Related]
11. Splenic irradiation for splenomegaly: A systematic review.
Zaorsky NG; Williams GR; Barta SK; Esnaola NF; Kropf PL; Hayes SB; Meyer JE
Cancer Treat Rev; 2017 Feb; 53():47-52. PubMed ID: 28063304
[TBL] [Abstract][Full Text] [Related]
12. Radiation therapy for palliation of Eisenmenger's syndrome-associated painful splenomegaly.
Osorio JI; Watkins JM; Strange C; Jenrette JM
Radiat Med; 2008 Feb; 26(2):84-7. PubMed ID: 18301984
[TBL] [Abstract][Full Text] [Related]
13. [Splenic irradiation in myeloid hemopathies: evaluation and toxicity].
Gonzague-Casabianca L; Bouabdallah R; Cowen D; Alzieu C; Richaud P; Resbeut M
Cancer Radiother; 1997; 1(3):213-21. PubMed ID: 9295875
[TBL] [Abstract][Full Text] [Related]
14. Splenic irradiation in chronic lymphocytic leukemia.
Chisesi T; Capnist G; Dal Fior S
Eur J Haematol; 1991 Apr; 46(4):202-4. PubMed ID: 2015875
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy of splenomegaly : a palliative treatment option for a benign phenomenon in malignant diseases.
Kriz J; Micke O; Bruns F; Haverkamp U; Mücke R; Schäfer U; Seegenschmiedt H; Müller RP; Eich HT
Strahlenther Onkol; 2011 Apr; 187(4):221-4. PubMed ID: 21424304
[TBL] [Abstract][Full Text] [Related]
16. Adaptive splenic radiotherapy for symptomatic splenomegaly management in myeloproliferative disorders.
Sager O; Beyzadeoglu M; Dincoglan F; Demiral S; Uysal B; Gamsiz H; Akin M; Gundem E; Dirican B
Tumori; 2015; 101(1):84-90. PubMed ID: 25702680
[TBL] [Abstract][Full Text] [Related]
17. Splenic irradiation as palliative treatment for symptomatic splenomegaly due to secondary myelofibrosis: a multi-institutional experience.
Pistevou-Gombaki K; Zygogianni A; Kantzou I; Kyrgias G; Mystakidou K; Kouvaris J; Klonizakis I; Tsirigotis P; Pappa V; Siakantari M; Eleftheriadis N; Georgakopoulos J; Sarris G; Kelekis N; Kouloulias V
J BUON; 2015; 20(4):1132-6. PubMed ID: 26416067
[TBL] [Abstract][Full Text] [Related]
18. Palliative irradiation of the spleen.
McFarland JT; Kuzma C; Millard FE; Johnstone PA
Am J Clin Oncol; 2003 Apr; 26(2):178-83. PubMed ID: 12714892
[TBL] [Abstract][Full Text] [Related]
19. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia.
Elliott MA; Chen MG; Silverstein MN; Tefferi A
Br J Haematol; 1998 Nov; 103(2):505-11. PubMed ID: 9827926
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
